I'll start, and then I'll turn to the officials to speak a little more about the review process in detail.
First of all, the member is right. We have purchased 56 million doses of Moderna and 20 million doses of Pfizer. That sets us up well in terms of our capacity with these two promising vaccines. We have also procured millions of doses from five others, AstraZeneca being one of them. Again, the vaccine task force has served us so well in guiding us towards very promising vaccines and placing our bets, if you will, on the right horses, so to speak, in the vaccine world.
In terms of the contractual obligations, that's probably a better question for the Minister of Procurement. Certainly I know that the contracts are extensive and complex, and I would prefer to let her answer questions around the details of contracts; she may know which aspects are confidential.
I will just say this. This has been a whole-of-government approach. I know that the Minister of Procurement has worked incredibly hard with all the companies, in some cases with personal calls to the CEOs. I myself have also met to encourage them to have Canada at the top of the list, and that has served us well, those personal relationships and that ongoing conversation with all the pharmaceutical companies to make sure they see Canada and they know that Canada matters and that even though we might be much smaller than our American counterpart, we are an important player in this space. I think that has served us well.
In terms of the regulatory approval, obviously, it's very important to Canadians that we have a Canadian review. I know we consult with other regulators, but I will turn to Stephen Lucas to talk about the nature of those conversations.